Watson To Pay $5.6B For Generic-Drug Maker Actavis
New Jersey-based Watson Pharmaceuticals Inc. has agreed to buy Swiss drugmaker Actavis Group for €4.25 billion (about $5.6 billion) in a deal that would create the world's third-largest generic pharmaceuticals maker,...To view the full article, register now.
Already a subscriber? Click here to view full article